Agilent Technologies Inc (A) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Jul 31 2026 to Jul 31 2025 - CSIMarket
Agilent Technologies Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Agilent Technologies Inc's ROI in the third quarter of 2026? Agilent Technologies inc achieved a return on average invested assets (ROI) of 19.84 % in its third quarter of 2026, this is above A's average return on investment of 12.68%. Agilent Technologies Inc s investments during the 12 months ending in the third quarter of 2026 are valued at $7 billion
ROI fell compared to the second quarter of 2026, despite the net income growth of 6.78% from the second quarter of 2026.
Within the Healthcare sector 54 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jul 31 2026 quarter, so far to 312, from total ROI ranking in the second quarter of 2026 at 568.
Santa Clara, Calif. - Agilent Technologies Inc. (NYSE: A), a leading figure in life sciences, diagnostics, and applied chemical markets, has once again demonstrated its commitment to pioneering innovation with the launch of its new Agilent JandW 5Q GC/MS Columns. This latest offering marks a significant milestone in gas chromatography/mass spectrometry (GC/MS) column technology, designed to enhance the performance and reliability of gas chromatographs. Technological Details and Applications: The Agilent JandW 5Q GC/MS Columns embody the cumulative experience of Agilent’s 50 years of leadership in gas chromatography. These columns integrate the acclaimed ultra-inert performance and ultra-low-bleed technology, which have become synonymous with Agilent’s products. The improvements are poised to push the boundaries of analytical chemistry, offering superior performance for complex sample analyses.
Agilent Technologies Expands Portfolio with $925 Million Acquisition of BiovectraIn a strategic move to enhance its service offerings to biotech companies and medical professionals, Agilent Technologies has announced its acquisition of contract drug manufacturer Biovectra for $925 million. The California-based biopharma firm aims to broaden its capabilities and solidify its position in the market through this lucrative deal.This acquisition comes after Agilent Technologies agreed to purchase Biovectra from HIG Capital for $1.3 billion CAD ($925 million USD). With this move, Agilent Technologies is set to benefit from Biovectra s expertise and expand its presence in the global pharmaceutical industry.
Agilent Technologies Announces CEO Transition and Commitment to Shareholders Santa Clara, Calif. - In a recent announcement, Agilent Technologies Inc. (NYSE: A) revealed that Padraig McDonnell, the president of the Agilent CrossLab Group (ACG), has been appointed the CEO-elect and chief operating officer (COO) of the company. He will succeed the current President and CEO Mike McMullen, who is set to retire. Alongside this transition, McDonnell will join Agilent s Board of Directors on May 1. Having dedicated nearly four decades to Agilent and its predecessor, Hewlett-Packard Co., McMullen will continue to contribute his expertise to the company even after his retirement. The appointment of McDonnell as Agilent s new president and CEO showcases the trust and confidence that the company places in his leadership abilities and vision for the future.
Financial Statements
Agilent Technologies Inc's III. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
